ema prac naion semaglutide Novo Nordisk refutes link between Wegovy and eye disease EMA's PRAC starts semaglutide review

Food and Drug Administration announced a new green list import alert aimed at stopping illegal and potentially dangerous GLP-1 drug ingredients from entering the country

Future Outlook Over the next five years, the India GLP-1 Receptor Agonist Market is projected to undergo significant growth fueled by the continuous rise in diabetes cases, enhanced awareness about chronic disease management, and ongoing innovations in drug formulations

The course includes the latest updates on the GLP-1 landscape, ensuring you're equipped with the most current information and strategies

1), GLP-1Rs have subsequently been localised to the central and peripheral nervous system, lung, kidney, gastrointestinal tract, heart and blood vessels [3], where they mediate a diverse number of actions distinct from control of glucose homeostasis [4]

Herz: Well, these start to sound in your description, not just like a revolution in obesity treatment, but a revolution in health, especially for people as they get older